Atenea Uribe-Ojeda

Dr. Atenea Uribe-Ojeda

Escuela de medicina, Universidad de Magallanes, Punta Arenas, Magallanes y de la Antártica Chilena, Chile
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2019 in Cells
Verified
Journal Article
Open access
PDF file
INIgnacio Niechi
Ignacio Niechi
AUAtenea Uribe-Ojeda
Atenea Uribe-Ojeda
JEJosé Ignacio Erices
José Ignacio Erices
ÁAÁngelo Sebastián Torres Arévalo
Ángelo Sebastián Torres Arévalo
DUDaniel Uribe
Daniel Uribe
CQClaudia Quezada
Claudia Quezada
Glioblastoma is the brain tumor with the worst prognosis. This is mainly due to a cell subpopulation with an extremely aggressive potential, called glioblastoma stem-like cells (GSCs). These cells produce high levels of extracellular adenosine, which are increased even more under hypoxic conditions. Under hypoxia, adenosine signaling is related to HIF-2α expression, enhancing cell aggressiveness. Adenosine can be degraded using recombinant adenosine deaminase (ADA) to revert its pathological effects. The aim of this study was to degrade adenosine using ADA in order to decrease malignancy of GSCs. Adenosine depletion was performed using recombinant ADA. Migration and invasion were measured by transwell and matrigel-coated transwell assay, respectively. HIF-2α-dependent cell migration/invasion decreased in GSCs treated with ADA under hypoxia. MRPs-mediated chemoresistance and colony formation decreased in treatment with ADA. In conclusion, adenosine depletion using adenosine deaminase decreases GSCs aggressiveness.